Atorvastatin cholesterol lowering intervention
systematic review meta-analysis network meta-analysis
 

Lipitor      

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathstroke (fatal and non fatal)

acute coronary syndrome  

MIRACL, 2001     atorvastatinplaceboacute coronary syndrome early initiation Low risk of bias suggesting-5%-50%
Colivicchi, 2002     atorvastatinusual careacute coronary syndrome early initiation Exploratory negative-23%-49%
ESTABLISH, 2004     atorvastatinusual careacute coronary syndrome early initiation Exploratory negative-100%
PROVE IT - TIMI 22, 2004     atorvastatinpravastatinacute coronary syndrome early initiation Low risk of bias suggesting-28%

acute myocardial infarction  

PROVE-IT, 2004         atorvastatin high dosepravastatindiabetic early initiation Low risk of bias suggesting18%

aortic stenosis  

SALTIRE, 2005     atorvastatinplaceboaortic stenosisLow risk of bias negative

atrial fibrillation  

Ozaydin, 2006     atorvastatincontrolExploratory suggesting
Dernellis, 2006     atorvastatinplaceboExploratory suggesting
MIRACL (sub-group) (Schwartz), 2004   atorvastatinplaceboLow risk of bias suggesting
Almroth, 2009     atorvastatin placeboLow risk of bias suggesting
ARMYDA-3 (AF ancillary study), 2006     atorvastatinplacebosuggesting
Chello, 2006     atorvastatinplaceboLow risk of bias negative
MIRACL (AF ancillary study), 2001     atorvastatinplaceboLow risk of bias negative

CABG surgery  

Patti et al., 2006     preoperative atorvastatinplaceboLow risk of bias suggesting-2%
Chello et al., 2006     preoperative atorvastatinplaceboLow risk of bias negative

cardiovascular prevention  

Mohler, 2003     atorvastatinplacebosecondary preventionLow risk of bias -
Deutsche Diabetes Dialyse Studie (4D), 2005   atorvastatinplaceboLow risk of bias suggesting-5%
MIRACL, 2001     atorvastatinplaceboacute coronary syndrome early initiation Low risk of bias suggesting-5%-50%
ASCOT (women subgroup) , 2003     AtorvastatinplacebowomenExploratory negative
ASPEN, 2006     atorvastatinplacebodiabetic patientsLow risk of bias negative2%-11%
Strey, 2005     atorvastatinplaceboheart failure -
SPARCL, 2006      NCTatorvastatinplacebopost stroke cerebral vascular disease Low risk of bias suggesting2%-15%
ASCOT (diabetics sub group), 2003   atorvastatinplacebodiabetic patients primary prevention Exploratory negative-33%
ASPEN, 2006     atorvastatinplacebodiabetic type 2 diabetes Low risk of bias negative-11%
Mohler III, 2003   atorvastatinplaceboPeripheral Arterial DiseaseExploratory -
ASPEN (primary prevention sub group), 2006     atorvastatinplacebodiabetic type 2 diabetes Low risk of bias negative6%-8%
CARDS, 2004      NCTatorvastatinplacebodiabetic type 2 diabetes Low risk of bias conclusive-26%-47%
macin, 2005     atorvastatinplaceboacute coronary syndrome squamous NSCLC Low risk of bias -
SALTIRE, 2005     atorvastatinplaceboaortic stenosisLow risk of bias negative
ASCOT, 2003   atorvastatinplaceboat risk hypertensive hypertensive patients Low risk of bias conclusive-13%-27%
Colivicchi, 2002     atorvastatinusual careacute coronary syndrome early initiation Exploratory negative-23%-49%
ESTABLISH, 2004     atorvastatinusual careacute coronary syndrome early initiation Exploratory negative-100%
GREACE, 2002     atorvastatinusual caresecondary preventionRisk of bias suggesting-43%-47%
AVERT, 1999     atorvastatin high doseangioplastysecondary preventionRisk of bias negative
TNT (diabetic sub group), 2006     atorvastatin high doseatorvastatindiabetic patients secondary prevention Low risk of bias suggesting10%-30%
TNT, 2005            NCTatorvastatin high doseatorvastatinsecondary preventionLow risk of bias conclusive 1%-24%
Vascular basis, 2005     atorvastatin high doselovastatinsecondary preventionExploratory negative∞%-48%
PROVE IT - TIMI 22, 2004     atorvastatinpravastatinacute coronary syndrome early initiation Low risk of bias suggesting-28%
PROVE-IT, 2004         atorvastatin high dosepravastatindiabetic early initiation Low risk of bias suggesting18%
REVERSAL, 2004     atorvastatin high dosepravastatinsecondary preventionExploratory negative0%
SAGE, 2007     atorvastatin high dosepravastatinsecondary preventionExploratory suggesting-67%-67%
IDEAL, 2005        NCTatorvastatin high dosesimvastatinsecondary preventionRisk of bias suggesting -2%-13%

diabetes type 2  

ASPEN, 2006     atorvastatinplacebodiabetic patientsLow risk of bias negative2%-11%
CARDS, 2004      NCTatorvastatinplacebodiabetic type 2 diabetes Low risk of bias conclusive-26%-47%
ASCOT (diabetics sub group), 2003   atorvastatinplacebodiabetic patients primary prevention Exploratory negative-33%
ASPEN (primary prevention sub group), 2006     atorvastatinplacebodiabetic type 2 diabetes Low risk of bias negative6%-8%
TNT (diabetic sub group), 2006     atorvastatin high doseatorvastatindiabetic patients secondary prevention Low risk of bias suggesting10%-30%

heart failure  

Wojnicz, 2006     atorvastatincontrolheart failurenegative
Yamada, 2007     atorvastatincontrolheart failurenegative-100%
Sola, 2006     atorvastatinplaceboheart failureLow risk of bias negative0%
Strey, 2005     atorvastatinplaceboheart failure -

hypertension  

ASCOT, 2003   atorvastatinplaceboat risk hypertensive hypertensive patients Low risk of bias conclusive-13%-27%

percutaneous coronary intervention  

NAPLES II (Briguori), 2009     atorvastatincontrolsuggesting
ARMYDA, 2004     atorvastatinplaceboLow risk of bias suggesting-71%
ARMYDA-RECAPTURE, 2009   atorvastatin reloadplaceboLow risk of bias suggesting-100%
GAIN, 2001     atorvastatinusual carenegative∞%

peripheral vascular diseases  

Mohler III, 2003   atorvastatinplaceboPeripheral Arterial DiseaseExploratory -

post myocardial infarction  

TNT, 2005            NCTatorvastatin high doseatorvastatinsecondary preventionLow risk of bias conclusive 1%-24%
Vascular basis, 2005     atorvastatin high doselovastatinsecondary preventionExploratory negative∞%-48%
REVERSAL, 2004     atorvastatin high dosepravastatinsecondary preventionExploratory negative0%
SAGE, 2007     atorvastatin high dosepravastatinsecondary preventionExploratory suggesting-67%-67%
IDEAL, 2005        NCTatorvastatin high dosesimvastatinsecondary preventionRisk of bias suggesting -2%-13%

post stroke  

SPARCL, 2006      NCTatorvastatinplacebopost stroke cerebral vascular disease Low risk of bias suggesting2%-15%



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons